University Health Network
A novel method to identify synergistic lethality in B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive lymphoma subtype in which relapse after front-line treatment remains a major challenge. Such patients have very poor outcomes. Better therapeutic strategies are thus urgently needed to increase upfront cure rates. We propose to uncover combinations of drug targets that, when inactivated, kill tumour cells synergistically. We are aiming to accelerate the discovery of promising drug combinations by using large-scale screens in which we can explore the effect of inactivating pairs of genes, in addition to inactivating such genes individually. Our goal is to uncover unexpected vulnerabilities and prioritize treatment strategies for subsequent clinical evaluation. Our project will discover novel ways of treating DLBCL patients including: identify strategies to improve upfront cure rates, decrease the morbidity from relapsed lymphoma, and ultimately improve survival of diffuse large B-cell lymphoma patients.